China Biologic Produ (CBPO)
China Biologic Privatization Transaction Led by Centurium Capital Wins AVCJ "Deal of the Year - Large Cap"
/PRNewswire/ -- The Centurium Capital-led privatization of leading plasma-based biopharmaceutical company China Biologic Products Holdings Inc. ("China...
China Biologic Announces Completion of Going Private Transaction
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020
BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, 'China Biologic' or the 'Company'), a leading fully ...
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020
China Biologic Products Holdings is Now Oversold (CBPO)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..
China Biologic Announces Shareholders' Approval of Merger Agreement
China Biologic Announces Extraordinary General Meeting of Shareholders
China Biologic Products Inc (CBPO) Q3 2020 Earnings Call Transcript
CBPO earnings call for the period ending September 30, 2020.
China Biologic Reports Financial Results for the Third Quarter of 2020
BEIJING, Nov. 24, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, 'China Biologic' or the 'Company'), a leading fully i...
China Biologic Reports Financial Results for the Third Quarter of 2020
China Biologic Enters into Definitive Merger Agreement for Going Private Transaction
China Biologic Products to Report Third Quarter 2020 Financial Results
BEIJING, Nov. 13, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ('China Biologic' or the 'Company'), a leading fully ...
China Biologic Products to Report Third Quarter 2020 Financial Results
CBPO Makes Bullish Cross Above Critical Moving Average
In trading on Thursday, shares of China Biologic Products Holdings Inc (CBPO) crossed above their 200 day moving average of $110.39, changing hands as high as $111.66 per share. China Biologic Products Holdings Inc shares are currently trading up about 1.4% on the day..
China Biologic Products Inc (CBPO) Q2 2020 Earnings Call Transcript
CBPO earnings call for the period ending June 30, 2020.
Update on China Biologic Products Q2 earnings (NASDAQ:CBPO)
China Biologic Products (CBPO -1.9%) Q2 reports total sales of $111.1M (-18.1% Y/Y).Gross profit decreased by 16.0% to $76.4M.Income from operations decreased by 11.4% to $42.7M from $48.2M last year.Non-GAAP adjusted net income decreased 10.9% to $43.4M.Non-GAAP EPS of $1.11, misses consensus.In April 2020, the company received approval from the Health Commission of Shandong Province to build a new plasma collection station in Yangxin County, Binzhou City of Shandong Province.Previously: China Biologic Products EPS misses by $0.17 (Aug.
China Biologic Reports Financial Results for the Second Quarter of 2020
BEIJING, Aug. 17, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, 'China Biologic' or the 'Company'), a leading fully i...
China Biologic Products EPS misses by $0.17 (NASDAQ:CBPO)
China Biologic Products (NASDAQ:CBPO): Q2 Non-GAAP EPS of $1.11 misses by $0.17; GAAP EPS of $0.91.Revenue of $111.1M (-18.1% Y/Y)Press Release
China Biologic Reports Financial Results for the Second Quarter of 2020
China Biologic Products to Report Second Quarter 2020 Financial Results
Best & Worst Performing Mid Cap Stocks for June 29, 2020
PCRX – PCRX leads the way today as the best performing mid cap stock, closing up 17.99%.
China Biologic Provides Additional Comments on the Xinjiang Deyuan and Shuanglin Transaction
China Inc. Pulls Out of U.S. Market at Fastest Pace Since 2015
Chinese companies are ditching their U.S. listings at the fastest pace since 2015 as they grapple with rising tensions between Beijing and Washington.
Best & Worst Performing Mid Cap Stocks for June 11, 2020
RETA – RETA leads the way today as the best performing mid cap stock, closing up 28.08%.
China Biologic Products Inc (CBPO) Q1 2020 Earnings Call Transcript
CBPO earnings call for the period ending March 31, 2020.
